Table 2

 Single-factor analyses of time-varying factors for progression of clinical damage

FactorSingle-factor analysesAll factors included
Relative damage rate (95% CI)p ValueRelative damage rate (95% CI)p Value
DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drug.
Functional class<0.0010.1
    Good (I)11
    Medium (II)1.56 (1.24 to 1.96)1.16 (0.89 to 1.5)
    Poor (III, IV)1.37 (0.96 to 1.91)0.87 (0.59 to 1.28)
Tender joints<0.0010.2
    None (0)11
    Low (1–4)1.45 (1.13 to 1.86)1.15 (0.89 to 1.51)
    Medium (5–9)1.63 (1.19 to 2.24)1.27 (0.91 to 1.78)
    High (>9)2.09 (1.54 to 2.85)1.37 (0.97 to 1.95)
Effusions<0.001<0.001
    None (0)11
    Low (1–4)1.32 (1.07 to 1.63)1.12 (0.89 to 1.42)
    Medium (5–9)1.84 (1.33 to 2.55)1.48 (1.02 to 2.13)
    High (>9)2.95 (1.82 to 4.78)2.6 (1.56 to 4.36)
ESR0.170.75
    Low (<15)11
    Medium (15–30)1.05 (0.82 to 1.39)0.99 (0.77 to 1.28)
    High (>30)1.27 (0.94 to 1.73)1.09 (0.8 to 1.48)
Arthritis duration0.67 (0.55 to 0.8) per extra decade in clinic<0.0010.73 (0.6 to 0.89)<0.001
Drugs0.1430.044
    None11
    NSAIDs0.72 (0.44 to 1.18)1.11 (0.65 to 1.91)
    DMARDs0.89 (0.6 to 1.32)1.32 (0.84 to 2.07)
    Steroids1.04 (0.68 to 1.6)1.64 (1.02 to 2.68)